Heparin Hasco (Heparin Sodium)

Q: What type of product is Heparin Hasco and how is it administered?

Heparin Hasco is a cutaneous (skin‑applied) formulation that contains heparin sodium and is administered by injection or topical application under prescription.

Q: Which clinical situations might lead a physician to prescribe Heparin Hasco?

Physicians may consider Heparin Hasco for preventing superficial thrombophlebitis after minor surgery, managing catheter‑related thrombosis, providing prophylaxis during immobilization, supporting hemodialysis access, or treating localized clotting disorders when systemic anticoagulation is not suitable.

Q: How does heparin sodium work to prevent clot formation?

Heparin sodium activates antithrombin III, which then inhibits thrombin and factor Xa, key enzymes in the coagulation cascade, thereby reducing the formation of fibrin clots.

Q: What are the most common side effects observed with Heparin Hasco?

Common side effects include minor bruising or hematoma at the injection site, localized redness or erythema, mild itching or skin irritation, and a temporary rise in aPTT without overt bleeding.

Q: What serious adverse reactions should patients be warned about?

Serious reactions can include heparin‑induced thrombocytopenia (HIT), major bleeding such as gastrointestinal hemorrhage, and allergic anaphylaxis presenting as hives, breathing difficulty, or low blood pressure.

Q: What laboratory tests are recommended before starting Heparin Hasco?

Baseline platelet count, activated partial thromboplastin time (aPTT), and other coagulation parameters should be measured to identify any pre‑existing abnormalities.

Q: Can Heparin Hasco be used during pregnancy?

Safety data for Heparin Hasco in pregnancy are limited; clinicians should weigh potential benefits against unknown risks and consider alternative anticoagulants when appropriate.

Q: Which medications should be avoided while a patient is receiving Heparin Hasco?

Concurrent use of other anticoagulants (e.g., warfarin, DOACs), antiplatelet agents (e.g., aspirin, clopidogrel), and fibrinolytic drugs should be avoided unless dose adjustments and close monitoring are in place.

Q: When should Heparin Hasco be used with caution?

Caution is advised when patients are also taking drugs that affect platelet count (such as carboplatin or quinine), medications that influence renal clearance, or when transitioning between vitamin K antagonists.

Q: What patient education points are important for those prescribed Heparin Hasco?

Patients should be instructed to monitor injection sites for bruising or excessive bleeding, report any unusual bruising, nosebleeds, blood in urine or stool, and seek immediate care if they experience signs of an allergic reaction or severe bleeding.

Heparin Hasco is a cutaneous formulation containing the anticoagulant heparin sodium. It is supplied in the European market as a prescription‑only product. The preparation delivers heparin sodium for local administration to support antithrombotic therapy. As an injectable or topical preparation, it works by activating antithrombin III, which reduces thrombin and factor Xa activity, thereby helping to prevent clot formation in clinical settings and may be used under medical supervision.

Manufacturer / TM Owner

Hasco-Lek

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Heparin Hasco is employed in situations where anticoagulation is required through a cutaneous route.

Prevention of superficial thrombophlebitis following minor surgical procedures.
Management of catheter‑related thrombosis in peripheral veins.
Adjunct therapy for patients at risk of clot formation during immobilization.
Prophylaxis of clot development in patients receiving hemodialysis access.
Supportive care for patients with localized clotting disorders when systemic anticoagulation is not indicated.

Side Effects

Adverse reactions to Heparin Hasco vary in frequency and severity.

Common

Minor bruising or hematoma at the injection site.
Localized redness or erythema.
Mild itching or skin irritation.
Transient elevation of activated partial thromboplastin time (aPTT) without clinical bleeding.

Serious

Heparin‑induced thrombocytopenia (HIT) with potential for new clot formation.
Major bleeding events such as gastrointestinal hemorrhage.
Allergic anaphylaxis manifesting as urticaria, dyspnea, or hypotension.

Precautions & Warnings

Before using Heparin Hasco, clinicians should evaluate several safety considerations.

Assess patient history for prior heparin exposure or known HIT.
Verify baseline platelet count and coagulation parameters.
Use caution in patients with active bleeding or recent major surgery.
Avoid in individuals with severe thrombocytopenia (<50,000/µL).
Consider pregnancy status; safety data are limited.
Monitor renal and hepatic function when prolonged therapy is planned.
Educate patients on signs of bleeding and when to seek medical attention.

Avoid Interactions

Heparin Hasco can interact with other agents that affect coagulation or platelet function.

Avoid

Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) without dose adjustment.
Combination with antiplatelet drugs such as aspirin, clopidogrel, or NSAIDs.
Administration with fibrinolytic agents (e.g., alteplase, streptokinase).

Use with caution

Concomitant therapy with drugs that may alter platelet count (e.g., carboplatin, quinine).
Use alongside medications that affect renal clearance, such as aminoglycosides.
Overlap with vitamin K antagonists during transition periods.

Frequently Asked Questions